AU Patent

AU2022339841A1 — Synthesis of nirogacestat

Assigned to SpringWorks Therapeutics Inc · Expires 2024-03-28 · 2y expired

What this patent protects

The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide ("nirogacestat").

USPTO Abstract

The present disclosures are directed to processes for synthesizing (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide ("nirogacestat").

Drugs covered by this patent

nirogacestat-hydrobromide (NIROGACESTAT HYDROBROMIDE)

Patent Metadata

Patent number: AU2022339841A1
Jurisdiction: AU
Classification: —
Expires: 2024-03-28
Drug substance claim: No
Drug product claim: No
Assignee: SpringWorks Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.